ECSP12011570A - Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb) - Google Patents
Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb)Info
- Publication number
- ECSP12011570A ECSP12011570A EC2012011570A ECSP12011570A ECSP12011570A EC SP12011570 A ECSP12011570 A EC SP12011570A EC 2012011570 A EC2012011570 A EC 2012011570A EC SP12011570 A ECSP12011570 A EC SP12011570A EC SP12011570 A ECSP12011570 A EC SP12011570A
- Authority
- EC
- Ecuador
- Prior art keywords
- pkb
- akt
- inhibitors
- phosphorilation
- pirimidin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a los nuevos productos de fórmula (I): en la que R1 representa arilo o heteroarilo sustituidos opcionalmente ; R representa H o bien forma con R1 un ciclo de 5 ó 6 eslabones fusionado a un resto arilo o heteroarilo que contiene opcionalmente uno o varios O, S, N, NH y Nalk, estando sustituido opcionalmente ; R2, R3 representan independientemente H, Hal o alquilo sustituido opcionalmente con uno o varios Hal ; R4 representa H; R5 representa un H o alquilo sustituido opcionalmente con uno o varios átomos de halógeno; estando estos productos en todas las formas isómeras y las sales, como medicamentos principalmente como inhibidores de fosforilación de AKT(PKB).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0903239A FR2947547B1 (fr) | 2009-07-02 | 2009-07-02 | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt (pkb) |
| US24110009P | 2009-09-10 | 2009-09-10 | |
| FR0957070A FR2951169B1 (fr) | 2009-10-09 | 2009-10-09 | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12011570A true ECSP12011570A (es) | 2012-02-29 |
Family
ID=42635553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2012011570A ECSP12011570A (es) | 2009-07-02 | 2012-01-03 | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb) |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US8791255B2 (es) |
| EP (1) | EP2448927B1 (es) |
| JP (1) | JP5680638B2 (es) |
| KR (1) | KR20120106714A (es) |
| CN (1) | CN102548970B (es) |
| AR (1) | AR077364A1 (es) |
| AU (1) | AU2010267816B2 (es) |
| CA (1) | CA2767064C (es) |
| CL (1) | CL2012000003A1 (es) |
| CO (1) | CO6480974A2 (es) |
| CR (1) | CR20110703A (es) |
| DK (1) | DK2448927T3 (es) |
| DO (1) | DOP2011000407A (es) |
| EA (1) | EA021088B1 (es) |
| EC (1) | ECSP12011570A (es) |
| ES (1) | ES2464125T3 (es) |
| HN (1) | HN2011003482A (es) |
| HR (1) | HRP20140478T1 (es) |
| IL (2) | IL217295A (es) |
| MA (1) | MA33501B1 (es) |
| ME (1) | ME01885B (es) |
| MX (1) | MX2012000094A (es) |
| MY (1) | MY153042A (es) |
| NI (1) | NI201200002A (es) |
| NZ (1) | NZ597579A (es) |
| PE (1) | PE20120640A1 (es) |
| PL (1) | PL2448927T3 (es) |
| PT (1) | PT2448927E (es) |
| RS (1) | RS53317B (es) |
| SG (2) | SG10201402867TA (es) |
| SI (1) | SI2448927T1 (es) |
| SM (1) | SMT201400084B (es) |
| TW (1) | TWI466883B (es) |
| UY (1) | UY32755A (es) |
| WO (1) | WO2011001114A1 (es) |
| ZA (1) | ZA201200026B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2969614A1 (fr) * | 2010-12-28 | 2012-06-29 | Sanofi Aventis | Nouveaux derives de pyrimidinones, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| FR2969610B1 (fr) * | 2010-12-28 | 2013-04-05 | Sanofi Aventis | Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-indolinamide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| FR2969609B1 (fr) * | 2010-12-28 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 6-oxo-dihydro-pyrimidine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb) |
| SI2658844T1 (sl) | 2010-12-28 | 2017-02-28 | Sanofi | Novi derivati pirimidina, njihova priprava in njihova farmacevtska uporaba kot inhibitorje AKT(PKB) fosforilacije |
| AU2012214413A1 (en) * | 2011-02-11 | 2013-08-22 | Dana-Farber Cancer Institute, Inc. | Method of inhibiting hamartoma tumor cells |
| EP2570127A1 (en) | 2011-09-16 | 2013-03-20 | Sanofi | Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors |
| EP2968350A1 (en) | 2013-03-15 | 2016-01-20 | Sanofi | Anti-tumoral composition comprising a pi3kbeta inhibitor and a raf inhibitor, to overcome cancer cells resistance |
| SG11201507720PA (en) | 2013-04-05 | 2015-10-29 | Sanofi Sa | Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor |
| WO2016086295A1 (en) | 2014-12-02 | 2016-06-09 | Millennium Stimulation Services Ltd. | Liquefied natural gas vaporizer for downhole oil or gas applications |
| WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI241298B (en) * | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
| ATE396978T1 (de) | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
| AU3042601A (en) | 2000-01-24 | 2001-07-31 | Thrombogenix Pty Ltd | Therapeutic morpholino-substituted compounds |
| GB0119865D0 (en) | 2001-08-14 | 2001-10-10 | Cancer Res Campaign Tech | DNA-PK inhibitors |
| US7365069B2 (en) * | 2002-04-10 | 2008-04-29 | Bexel Pharmaceuticals Inc. | Pyrimidone derivatives |
| WO2004016607A1 (en) | 2002-08-16 | 2004-02-26 | Kinacia Pty Ltd. | Inhibition of phosphoinositide 3-kinase beta |
| EP1682532B1 (en) * | 2003-10-31 | 2007-06-27 | Warner-Lambert Company LLC | Pyrimidines as inhibitors of phosphoinositide-3-kinases (pi3k) |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| AR053358A1 (es) | 2005-04-15 | 2007-05-02 | Cancer Rec Tech Ltd | Inhibidores de adn - pk |
| EP1895997A2 (en) | 2005-05-26 | 2008-03-12 | Kudos Pharmaceuticals Ltd | Use of dna-pk inhibition to sensitise atm deficient cancers to dna-damaging cancer therapies |
| US7700592B2 (en) | 2005-08-25 | 2010-04-20 | Schering Corporation | α2C adrenoreceptor agonists |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| WO2008064244A2 (en) | 2006-11-20 | 2008-05-29 | The Trustees Of Columbia University In The City Of New York | Phosphoinositide modulation for the treatment of neurodegenerative diseases |
| WO2008148074A2 (en) | 2007-05-24 | 2008-12-04 | Research Foundation Of State University Of New York | Inhibitors of mtor and methods of treatment using same |
| CA2692945A1 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Compounds - 945 |
| CN101796048A (zh) * | 2007-07-09 | 2010-08-04 | 阿斯利康(瑞典)有限公司 | 用于治疗增殖病症的三取代的嘧啶衍生物 |
| US20100227858A1 (en) | 2007-07-09 | 2010-09-09 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| EA018708B1 (ru) | 2007-07-09 | 2013-10-30 | Астразенека Аб | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K |
| AR074072A1 (es) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
-
2010
- 2010-07-01 PL PL10742014T patent/PL2448927T3/pl unknown
- 2010-07-01 DK DK10742014.3T patent/DK2448927T3/da active
- 2010-07-01 AU AU2010267816A patent/AU2010267816B2/en not_active Ceased
- 2010-07-01 SI SI201030607T patent/SI2448927T1/sl unknown
- 2010-07-01 HR HRP20140478AT patent/HRP20140478T1/hr unknown
- 2010-07-01 SG SG10201402867TA patent/SG10201402867TA/en unknown
- 2010-07-01 CA CA2767064A patent/CA2767064C/fr not_active Expired - Fee Related
- 2010-07-01 WO PCT/FR2010/051375 patent/WO2011001114A1/fr not_active Ceased
- 2010-07-01 KR KR1020127002839A patent/KR20120106714A/ko not_active Abandoned
- 2010-07-01 EP EP10742014.3A patent/EP2448927B1/fr active Active
- 2010-07-01 RS RS20140306A patent/RS53317B/sr unknown
- 2010-07-01 ME MEP-2014-62A patent/ME01885B/me unknown
- 2010-07-01 ES ES10742014.3T patent/ES2464125T3/es active Active
- 2010-07-01 PE PE2012000004A patent/PE20120640A1/es not_active Application Discontinuation
- 2010-07-01 CN CN201080039214.XA patent/CN102548970B/zh not_active Expired - Fee Related
- 2010-07-01 NZ NZ597579A patent/NZ597579A/xx not_active IP Right Cessation
- 2010-07-01 JP JP2012518120A patent/JP5680638B2/ja not_active Expired - Fee Related
- 2010-07-01 MX MX2012000094A patent/MX2012000094A/es active IP Right Grant
- 2010-07-01 MY MYPI2011006377 patent/MY153042A/en unknown
- 2010-07-01 AR ARP100102350A patent/AR077364A1/es unknown
- 2010-07-01 EA EA201270111A patent/EA021088B1/ru not_active IP Right Cessation
- 2010-07-01 PT PT107420143T patent/PT2448927E/pt unknown
- 2010-07-01 SG SG2011097938A patent/SG177469A1/en unknown
- 2010-07-01 MA MA34593A patent/MA33501B1/fr unknown
- 2010-07-02 TW TW99121906A patent/TWI466883B/zh not_active IP Right Cessation
- 2010-07-02 UY UY0001032755A patent/UY32755A/es not_active Application Discontinuation
-
2011
- 2011-12-21 CR CR20110703A patent/CR20110703A/es unknown
- 2011-12-26 DO DO2011000407A patent/DOP2011000407A/es unknown
- 2011-12-27 US US13/338,011 patent/US8791255B2/en not_active Expired - Fee Related
- 2011-12-29 CO CO11180700A patent/CO6480974A2/es active IP Right Grant
- 2011-12-29 IL IL217295A patent/IL217295A/en not_active IP Right Cessation
- 2011-12-30 HN HN2011003482A patent/HN2011003482A/es unknown
-
2012
- 2012-01-01 IL IL217321A patent/IL217321A0/en unknown
- 2012-01-02 CL CL2012000003A patent/CL2012000003A1/es unknown
- 2012-01-03 ZA ZA2012/00026A patent/ZA201200026B/en unknown
- 2012-01-03 EC EC2012011570A patent/ECSP12011570A/es unknown
- 2012-01-05 NI NI201200002A patent/NI201200002A/es unknown
-
2014
- 2014-06-23 US US14/312,124 patent/US8993565B2/en not_active Expired - Fee Related
- 2014-06-26 SM SM201400084T patent/SMT201400084B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12011570A (es) | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb) | |
| CO6400223A2 (es) | Derivados de 6-(6-o-sustituido-triazolopiridazina-sulfanil)benzotiazoles y bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met | |
| CO6331467A2 (es) | Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met | |
| CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
| UY30105A1 (es) | Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas. | |
| CO6331463A2 (es) | Nuevos derivados de triazolo(4,3-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met | |
| NI201100020A (es) | NUEVOS DERIVADOS DE IMIDAZO[1,2-a] PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDOR DE MET. | |
| BR112014006660A2 (pt) | novos derivados de dihidroquinolina-2-ona bicíclicos | |
| CY1110489T1 (el) | Παραγωγα ισοκινολινης | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| UY30409A1 (es) | Pirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos. | |
| CU20100157A7 (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR087487A1 (es) | Compuestos heterociclicos derivados de pirimidina como inhibidores de las kinasas activadas janus (jak) | |
| UY32753A (es) | NUEVOS DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA, SU PREPARACIÓN Y SU UTILIZACIÓN EN FARMACÉUTICA | |
| PL401473A1 (pl) | Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania | |
| MX2015013365A (es) | Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag). | |
| EA201591819A1 (ru) | Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10) | |
| CO6420339A2 (es) | Derivados de 6-(6-sustituido-triazolopiridacina-sulfanil) 5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met | |
| MX2015013374A (es) | Derivados de urea y su uso como inhibidores de proteina de uniuon a acidos grasos (puag). | |
| UY32756A (es) | Nuevos derivados de 1h-pirimidin-2-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fos-forilacion de akt (pkb) | |
| BR112015023280A2 (pt) | derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase | |
| UY29390A1 (es) | Derivados nuevos de 3-aril-1,2-bencisoxazol, composiciones que los contienen y su utilización. | |
| CU20120041A7 (es) | Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| NI201000111A (es) | Nuevos derivados de acido 2-mercaptociclopentanocarboxilico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| CY1115626T1 (el) | Νεα παραγωγα (6-οξο-1,6-διυδρο-πυριμιδιν-2-υλ)-αμιδιο, η παρασκευη τους και η φαρμακευτικη χρηση τους ως αναστολεις φωσφορυλιωσης του ακτ |